
Antheia CEO on How Biomanufacturing can De-Risk Pharmaceutical Production
In a recent Q&A with European Pharmaceutical Manufacturer Antheia CEO and co-founder Dr. Christina Smolke discussed how latency...
Antheia CEO on How Biomanufacturing can De-Risk Pharmaceutical Production
Antheia CEO Presents at CPHI on Transforming Pharma Supply Chains [Watch]
Demystifying Synthetic Biology Part V: The Product is Key in Downstream Processing
Introducing Guerin Kob, Antheia’s VP of Supply Chain
Demystifying Synthetic Biology IV: Fermentation Bioprocess Development
Demystifying Synthetic Biology III: The 21st Century Technologies Advancing Synthetic Biology
Introducing CPO Heidi Pucel
Demystifying Synthetic Biology II: Molecular Biology Advancements Enabling Synthetic Biology
Demystifying Synthetic Biology: Building with the power of biology
Introducing Zack McGahey, Antheia’s COO
Join the Movement to Build a Century-Defining Technology
Fixing essential medicine shortages: obstacles and opportunities
Investing in the next wave of biomanufacturing technologies for pharma
Meet the Team - Our Lab Operations Team
Scaling synthetic biology as a manufacturing platform
Meet the Team - Our Engineer, Yuki Higa
Meet the Team – Our RA, Cat Cleto
Antheia at SynBioBeta 2020
Meet the Team - Our Scientist, Ken Takeoka
A Milestone for Drug Manufacturing and Synthetic Biology: Stanford Research Published in Nature